UK-based Vaccitech has started treating patients with influenza A vaccine MVA-NP+M1 (VTP-100) in a Phase IIb clinical trial.
Located in Antwerp, Belgium, the trial will recruit a total of 155 individuals, which will be administered with either VTP-100 or placebo.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Designed to prevent both seasonal influenza and pandemics, VTP-100 triggers enhanced immune protection against all influenza A strains. It uses a replication-deficient pox viral vector called MVA to produce a strong immune response against Matrix 1 (M1) and Nucleoprotein (NP) influenza antigens.
Dubbed Flu 010, the Phase IIb trial is intended to evaluate VTP-100’s protective capabilities as a standalone vaccine for use in a future pandemic or pre-pandemic influenza.
Of the total participants, 134 will receive the A/Belgium/4217/2015 (H3N2) influenza virus strain.
Vaccitech expects study data to be available early next year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company noted that its Australian subsidiary has completed vaccination of 2,200 participants in a double-blind, randomised, placebo-controlled Flu 009 Phase IIb field trial being conducted in the country.
This trial will assess VTP-100’s additive protective efficacy against influenza-like illness when given in adjunction with existing licenced quadrivalent influenza seasonal vaccines (QIV).
Outpatients that received standard-of-care QIV earlier in the influenza season were enrolled at nine sites across Australia. The trial will investigate if VTP-100 + QIV could provide better efficacy over QIV alone.
Interim results from the trial are expected early next year. Based on the findings, the company intends to continue the study for a second season and enrol up to 6,000 participants overall in Australia.
Vaccitech CEO Tom Evans said: “We expect positive data to support the positioning of VTP-100 as a vaccine that can reduce the burden of influenza, both as a pre-pandemic intervention and as an add-on to a seasonal vaccine, especially in high-risk individuals.”
